

Hitting the Bullseye With Anti-BCMA Treatment – Clinical Brief #1

References

Tweet 6

BLENREP (belantamab mafodotin-blmf) [prescribing information]. GlaxoSmithKline. Approved 2020. Revised February 2022.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761158s006lbl.pdf

CARVYKTI™ (ciltacabtagene autoleucel) [prescribing information]. Janssen Biotech, Inc. Approved 2022. Revised February 2022. <https://www.fda.gov/media/156560/download>

ABECMA® (idecabtagene vicleucel) [prescribing information]. Bristol-Myers Squibb. Approved 2021. Revised March 2021. <https://www.fda.gov/media/147055/download>

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Multiple Myeloma (v5.2022). Updated March 9, 2022. Accessed June 2, 2022. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

Glossary

ADC, antibody-drug conjugate
ADL, activity of daily living
AE, adverse event
BCMA, B cell maturation antigen
BCVA, best-corrected visual acuity
Belamaf, belantamab mafodotin
CAR, chimeric antigen receptor
IMiD, immunomodulatory drug
LOT, line of therapy
mAb, monoclonal antibody
mDOR, median duration of response
MM, multiple myeloma
mOS, median overall survival
mPFS, median progression-free survival
MRD, minimal residual disease
NR, not reached
ORR, overall response rate
PI, proteasome inhibitor
RRMM, relapsed/refractory multiple myeloma
VGPR, very good partial response